Introduction:

Two-stage revision is a widely accepted and performed intervention for septic total knee arthroplasty (TKA), with an infection eradication rate exceeding 90% in most studies. The ‘2-in-1’ single stage revision has recently been reported to have favourable results.

Blood loss following total hip replacement is a major contributor to increase morbidity and length of stay. Various techniques have been described to reduce its occurrence. We now follow a set protocol, combining rivaroxaban for thrombo-prophylaxis and tranexamic acid to reduce immediate postoperative bleeding.

The risk of venous thrombo-embolism (VTE) is high in orthopedics. Oral direct factor Xa inhibitors have been introduced to help reduce the incidence of VTE. To reduce post-operative bleeding antifibrinolytics are used. We aimed to ascertain the effect of two drugs on post operative bleeding and transfusion requirements.

We prospectively recorded patient demographics, operative details, complications, transfusion incidence and VTE incidence in TKR patients. We also sent out questionnaires to patients asking about wound bleeding and VTE. All patients were given 10mg Rivaroxaban 8 hours post operatively and then OD for 14 or 35 days. Patients given tranexamic acid were given 500mg IV, 5 minutes prior to wound closure at the discretion of the surgeon. VTE was Deep Vein Thrombus or Pulmonary Embolism confirmed by Doppler or CTPA. Minor bleed was categorized as dressing soakage or reported wound leakage, major bleed as hematoma requiring revision within 30 days.

509 patients underwent TKR: 200 (39%) received Rivaroxaban only (Group 1), 296 (58%) also received tranexamic acid (Group 2). 13 (3%) patients had no data available. Five patients had a VTE: 4 (2%) in Group 1, 1 (0.3%) in Group 2 [P<0.05]. 39 patients had a minor bleed: 17 (8.5%) in Group 1, 22 (7.4%) in Group 2 [P=0.5]. 2 patients had major bleeds: 1(0.5%) in Group 1 and 1(0.33%) in Group 2 [P=0.69]. There were 30 blood transfusions: 21 (10.5%) in Group 1, 9 (3%) in Group 2 [P<0.0001].

We have demonstrated a reduced requirement for blood transfusions in the tranexamic acid group. However our results, whilst they show a trend towards decreased minor and major bleeding rates, are not significant and require larger studies looking at wound bleeding and leakage.

The risk of venous thrombo-embolism (VTE) is high in orthopaedics. Oral direct factor Xa inhibitors have been introduced to help reduce the incidence of VTE. To reduce post-operative bleeding antifibrinolytics are used. We aimed to ascertain the effect of two drugs on post-operative bleeding and transfusion requirements.

We prospectively recorded patient demographics, operative details, complications, transfusion incidence and VTE incidence in TKR patients. We also sent out a questionnaire to patients asking about wound bleeding and VTE. All patients were given 10mg Rivaroxaban 8 hours post operatively and then once a day for 14 days. Patients given tranexamic acid were given 500mg IV, 5 minutes prior to wound closure at the discretion of the surgeon. VTE was confirmed by Doppler or CTPA as Deep Vein Thrombus or Pulmonary Embolism. Minor bleed was categorised as dressing soakage or reported wound leakage, major bleed as haematoma requiring revision within 30 days.

509 patients underwent TKR: 200(39%) only received Rivaroxaban (Group 1), 296(58%) also received tranexamic acid (Group 2). 13(3%) of patients had no data available. 5 patients had a VTE: 4 (2%) Group 1, 1 (0.3%) Group 2 (P<0.05). 39 patients had a minor bleed: 17 (8.5%) Group 1, 22 (7.4%) Group 2 (P=0.5). 2 patients had major bleeds: 1 (0.5%) Group 1, 1 (0.33%) Group 2 (P=0.69). Blood transfusions 21: (10.5%)Group 1, 9 (3%) Group 2 (P<0.0001).

We have demonstrated a reduced requirement for blood transfusions in the tranexamic acid group. However our results whilst they show a trend towards decrease bleeding rates in both the minor and major bleeds are not significant, requiring larger studies looking at wound bleeding and leakage.

Rivaroxiban is a factor Xa inhibitor and is a newer oral alternative for thromboprophylaxis after joint replacements. Its major advantage is its oral administration and hence better patient compliance. However there are some doubts about its efficacy compared to dalteparin/heparin. We have recently changed over from using dalteparin injections to rivaroxiban tablets for thromboprophylaxis after hip replacements. We assessed our results to find efficacy and specificity of its action in patients undergoing THR.

504 patients underwent hip replacement in last 2 years. 316 were treated with dalteparin injections (fragmin) for thromboprophylaxis while 189 patients were treated with oral rivaroxiban for 35 days after their hip replacement.

Average haemoglobin drop at 24 hours postop was 2.79 in Rivaroxiban group compared to 3. 10 in dalteparin group. 19 patients (of 189 i.e. 10.05%) required postop blood transfusion in rivaroxiban group as against 60 (of 315 i.e. 19.04%) in Dalteparin group. This difference was statistically significant. Incidence of DVT was no different in either groups, but the number of patients was too small to compare this.

Rivaroxiban appears to be more specific in its action and our results suggest a significant reduction in postop blood transfusion following hip replacements without any increase in rate of Deep Vein Thrombosis. We would like to present our findings and discuss role of oral thromboprophylaxis after joint replacements.

Introduction: With an aging population, the number of hemiarthroplasties and Total Hip Replacements is on a rise. Though uncommon, one of the serious postoperative complications is periprosthetic fracture of femur. Dall Miles cable plate system is widely used for fixation of these fractures.

Patient and Methods: We present a series of of 19 patients who underwent Dall Miles cable plate fixation for periprosthetic fracture over a hemiarthroplasty or a total hip replacement during the last 5 years, reporting clinical and radiological outcome measures.

Results: Female to male ratio was 2:1. The average age was 77.33 (range from 55 to 93). Eight patients had the periprosthetic fracture after hemiarthroplasty while 11 had it after Total Hip Replacement. These two group were completely different in terms of their fitness, activities and expectations. Twelve were Vancouver B 1, 7 were Vancouver C. Five were initially managed with two plates, the remainder had one plate only.

Patients were followed up at an average of 3.1 years (range 3.2 months to 5.1 years). Three patients had died at the time of our follow up due to unrelated medical problems. One patient had deep infection that required revision and 1 had superficial infection that healed with antibiotics. 1 patient underwent revision to a THR for hip pain.

Of those managed with a single plate, 3 patients had plate/cable failure and underwent revision DM plating with 2 plates and cables along with allogenic bone grafting; all of these healed well. All of these patients had periprosthetic # following a THR.

Five patients managed initially with 2 DM plates healed without any complications.

Discussion: Even in this small series, we feel it is evident that Dall Miles plating using a single plate has a high incidence of plate failure (3 of 13). Orthogonal plating has been widely used in past for fixation of complex fractures and nonunions. We feel there is a distinct advantage of using two plates of uneven lengths to improve chances of healing, preventing implant failure and reducing stress riser effect. We advocate primary fixation of periprosthetic fractures of proximal femur over THR using 2 Dall Miles cable plates and bone graft. We would like to present our results and discuss this complex topic further.

Background: Intracapsular neck of femur fracture (# ICNOF) is one of the most common fractures in the elderly. In octa and nonagenarians, with age associated and other co morbidities, achieving a pre injury status of mobility is the deemed result. The physiological age, rather than the chronological one is an important factor determining the type of joint used and results in these patients.

Aim: We present here, a study of 349 patients in the age group of 80 to 100, who underwent hemiarthroplasty as primary treatment for # ICNOF.

Patients and Methods: We studied the data from a prospective hip database of patients undergoing hemiarthroplasty for # ICNOF between Jan 2000 and Jan 2005. All patients admitted with # ICNOF in our centre are assessed by a Hip audit nurse. Pre and post operative data is collected in a specific format. Patients undergo hemi-arthroplasty usually within 24 hours of admission. The type of joint used in decided by the operating surgeon. Patients were reviewed at the 4 month mark after the surgery. They were assessed for pain, mobility and complications. Seven outcomes and eight possible confounding factors were considered and statistical comparison was done to find specific correlation between these factors.

Results: 613 patients underwent hemiarthroplasty during the said period. 349 of these were more than 80 years of age. The mortality and mobility in this group was studied and various factors determining the outcome were assessed and statistical correlation tested. The mortality was expectedly higher in elderly population. Post operative mobility was mainly related to the preoperative functional status. In addition, age, other co-morbidities, ASA grade and joint type also had bearing on the Results:

Discussion: We are a busy District General Hospital in Scotland and hemiarthroplasty for # ICNOF is one of the routinely performed surgeries with more than 100 patients undergoing this procedure in a year. We have a dedicated Hip audit nurse who is responsible for maintaining a database for all these patients.

With increasing age of the population, # ICNOF in over 80s has evolved into a commonly encountered problem. Early mobilisation and aiming for pre injury functional status is an achievable goal in most. ‘The better they walked before, the better they will walk after’ is the golden rule to predict outcome. We use uncemented Austin Moore prosthesis for all patients but prefer to use a bipolar uncemented HAP coated prosthesis (JRI Furlong prosthesis) for patients who are relatively active and independent, regardless their age. The early results in this second group of patients are predictably better, but it will require further detailed study to determine whether these hold true in long term as well.